Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Consolidated Net Income: 2009-2025

Historic Consolidated Net Income for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $338.7 million.

  • UNITED THERAPEUTICS's Consolidated Net Income rose 9.58% to $338.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 14.47%. This contributed to the annual value of $1.2 billion for FY2024, which is 21.35% up from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Consolidated Net Income stood at $338.7 million for Q3 2025, which was up 9.43% from $309.5 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's 5-year Consolidated Net Income high stood at $338.7 million for Q3 2025, and its period low was $28.3 million during Q1 2021.
  • Moreover, its 3-year median value for Consolidated Net Income was $301.3 million (2024), whereas its average is $286.4 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first tumbled by 79.45% in 2021, then surged by 747.70% in 2022.
  • UNITED THERAPEUTICS's Consolidated Net Income (Quarterly) stood at $112.2 million in 2021, then rose by 17.74% to $132.1 million in 2022, then skyrocketed by 64.35% to $217.1 million in 2023, then soared by 38.78% to $301.3 million in 2024, then increased by 9.58% to $338.7 million in 2025.
  • Its Consolidated Net Income was $338.7 million in Q3 2025, compared to $309.5 million in Q2 2025 and $322.2 million in Q1 2025.